Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Aug 31;57(4):331-42.
doi: 10.3325/cmj.2016.57.331.

Conjugated Linoleic Acid Improves Glycemic Response, Lipid Profile, and Oxidative Stress in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

Affiliations
Free PMC article
Randomized Controlled Trial

Conjugated Linoleic Acid Improves Glycemic Response, Lipid Profile, and Oxidative Stress in Obese Patients With Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial

Mehrangiz Ebrahimi-Mameghani et al. Croat Med J. .
Free PMC article

Abstract

Aim: To investigate if conjugated linoleic acid supplementation (CLA) affects metabolic factors and oxidative stress in non-alcoholic fatty liver disease (NAFLD).

Methods: The study was a randomized, controlled clinical trial conducted in specialized and subspecialized clinics of Tabriz University of Medical Sciences from January 2014 to March 2015. 38 obese NAFLD patients were randomly allocated into either the intervention group, receiving three 1000 mg softgel of CLA with a weight loss diet and 400 IU vitamin E, or into the control group, receiving only weight loss diet and 400 IU vitamin E for eight weeks. Dietary data and physical activity, as well as anthropometric, body composition, metabolic factors, and oxidative stress were assessed at baseline and at the end of the study.

Results: Weight, body composition, and serum oxidative stress, insulin, and lipid profile significantly improved in both groups, while hemoglobin A1c (HbA1c) levels (P=0.004), total cholesterol to high density lipoprotein ratio (P=0.008), low density lipoprotein to high density lipoprotein ratio (LDL/HDL) (P=0.002), and alanine aminotransferase to aspartate aminotransferase (ALT/AST) ratio (P=0.025) significantly decreased in the intervention group. At the end of the study, fat mass (P=0.001), muscle mass (P=0.023), total body water (P=0.004), HbA1c (P<0.001), triglycerides (P=0.006), LDL/HDL ratio (P=0.027), and ALT/AST ratio (P=0.046) were significantly better in the CLA group than in the control group.

Conclusion: CLA improved insulin resistance, lipid disturbances, oxidative stress, and liver function in NAFLD. Therefore, it could be considered as an effective complementary treatment in NAFLD.

Figures

Figure 1
Figure 1
Flowchart of the study.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Ebrahimi-Mameghani M, Aliashrafi S, Javadzadeh Y. AsghariJafarabadi M. The effect of microalgae chlorella vulgaris supplementation on lipid profile and lipid peroxidation in non-alcoholic fatty liver disease: a double- blind randomized clinical trial. Health Promotion Perspectives. 2014;4:107–15. - PMC - PubMed
    1. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277–83. doi: 10.1161/CIRCULATIONAHA.107.739920. - DOI - PMC - PubMed
    1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–50. doi: 10.1056/NEJMra0912063. - DOI - PubMed
    1. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Patients in India (SPRINT). J Assoc Physicians India. 2013;61:448–53. - PubMed
    1. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25:1045–50. doi: 10.1161/01.ATV.0000160613.57985.18. - DOI - PubMed

Publication types

Feedback